NCT00853047 - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Carcinoid Syndrome

Interventions

DRUG

Telotristat etiprate

Telotristat etiprate capsules; orally 3 times daily.

DRUG

Octreotide LAR Depot

A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

DRUG

Placebo

Placebo-matching telotristat etiprate capsules; orally 3 times daily.

Trial Locations (9)

St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis

University of Iowa, Iowa City

Nebraska Methodist Hospital, Omaha

Hematology Oncology Services of Arkansas, Little Rock

UT M.D. Anderson Cancer Center, Houston

Texas Oncology - McAllen, McAllen

Texas Oncology - Weslaco, Weslaco

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Dana Farber Cancer Institute, Boston